A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SI-B001+SI-B003 With or Without Chemotherapy (SI-B001+SI-B003± Chemotherapy) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 07 Aug 2025
At a glance
- Drugs Danvilostomig (Primary) ; Izalontamab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 28 Nov 2023 Planned End Date changed from 1 Aug 2025 to 1 Nov 2025.
- 28 Nov 2023 Planned primary completion date changed from 1 Aug 2025 to 1 Nov 2025.
- 28 Nov 2023 Status changed from not yet recruiting to recruiting.